4//SEC Filing
Nichols William Garrett 4
Accession 0000950170-25-042728
CIK 0001841387other
Filed
Mar 19, 8:00 PM ET
Accepted
Mar 20, 4:36 PM ET
Size
13.4 KB
Accession
0000950170-25-042728
Insider Transaction Report
Form 4
Nichols Garrett
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-18$1.29/sh+13,905$17,937→ 97,809 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-18−4,584→ 195,416 totalExercise: $3.75Exp: 2032-09-12→ Common Stock (4,584 underlying) - Exercise/Conversion
Common Stock
2025-03-18$3.75/sh+4,584$17,190→ 83,904 total - Sale
Common Stock
2025-03-18$8.76/sh−45,316$396,995→ 52,493 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-18−13,905→ 31,095 totalExercise: $1.29Exp: 2033-04-28→ Common Stock (13,905 underlying)
Footnotes (4)
- [F1]This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.36 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.
- [F3]The first 100,000 shares underlying this option shall vest as follows: 25% shall vest and become exercisable on September 12, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. The remaining 100,000 shares underlying this option shall vest as follows: 25% shall vest and become exercisable on the first anniversary of the date in which the Reporting Person converts to a full-time employee, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- [F4]This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date.
Documents
Issuer
Candel Therapeutics, Inc.
CIK 0001841387
Entity typeother
Related Parties
1- filerCIK 0001618364
Filing Metadata
- Form type
- 4
- Filed
- Mar 19, 8:00 PM ET
- Accepted
- Mar 20, 4:36 PM ET
- Size
- 13.4 KB